{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:12:31Z","timestamp":1781071951263,"version":"3.54.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.thromres.2022.01.008","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T08:27:08Z","timestamp":1653553628000},"page":"S16-S21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"S1","title":["Venous thromboembolism and risk stratification in hematological malignancies"],"prefix":"10.1016","volume":"213","author":[{"given":"Kristen M.","family":"Sanfilippo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2022.01.008_bb0005","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2022.01.008_bb0010","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.ejca.2012.10.021","article-title":"Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases","volume":"49","author":"Walker","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.thromres.2022.01.008_bb0015","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.01.008_bb0020","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2022.01.008_bb0025","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2022.01.008_bb0030","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2022.01.008_bb0035","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1182\/blood-2008-08-175745","article-title":"Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival","volume":"113","author":"Ku","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2022.01.008_bb0040","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/j.1538-7836.2005.01467.x","article-title":"The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment","volume":"3","author":"De Stefano","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.01.008_bb0045","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1182\/blood-2006-04-015511","article-title":"Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients","volume":"108","author":"Caruso","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2022.01.008_bb0050","first-page":"328","article-title":"Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study","volume":"136","author":"Orvain","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2022.01.008_bb0055","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/bloodadvances.2018023895","article-title":"Venous thromboembolism in chronic lymphocytic leukemia: a danish nationwide cohort study","volume":"2","author":"Gade","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2022.01.008_bb0060","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/jth.14475","article-title":"Risk of thromboembolic and bleeding outcomes following hematological cancers: a danish population-based cohort study","volume":"17","author":"Adelborg","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.01.008_bb0065","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2018-01-827949","article-title":"Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years","volume":"131","author":"Rank","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2022.01.008_bb0070","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1182\/blood-2016-02-701094","article-title":"Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia","volume":"128","author":"Libourel","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2022.01.008_bb0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12959-019-0202-z","article-title":"Validation of the khorana score in acute myeloid leukemia patients: a single-institution experience","volume":"17","author":"Mirza","year":"2019","journal-title":"Thromb. J."},{"key":"10.1016\/j.thromres.2022.01.008_bb0080","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1055\/s-0039-3400303","article-title":"Development of a clinical prediction rule for venous thromboembolism in patients with acute leukemia","volume":"120","author":"Al-Ani","year":"2020","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.01.008_bb0085","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1182\/blood-2010-01-263012","article-title":"Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study","volume":"115","author":"Mitchell","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2022.01.008_bb0090","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.thromres.2012.03.019","article-title":"Incidence, risk factors and clinical features of venous thromboembolism in newly diagnosed lymphoma patients: results from a prospective cohort study with asian population","volume":"130","author":"Park","year":"2012","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2022.01.008_bb0095","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/10428190600560991","article-title":"Venous thromboembolism in patients with diffuse large B-cell lymphoma","volume":"47","author":"Komrokji","year":"2006","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.thromres.2022.01.008_bb0100","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.thromres.2016.05.008","article-title":"Incidence of venous thromboembolism in patients with non-hodgkin lymphoma","volume":"143","author":"Sanfilippo","year":"2016","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2022.01.008_bb0105","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/cncr.11623","article-title":"High incidence of thromboembolism in patients with central nervous system lymphoma","volume":"98","author":"Goldschmidt","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.thromres.2022.01.008_bb0110","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.amjmed.2010.05.021","article-title":"Incidence and risk factors of venous thromboembolic events in lymphoma","volume":"123","author":"Zhou","year":"2010","journal-title":"Am. J. Med."},{"key":"10.1016\/j.thromres.2022.01.008_bb0115","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.clml.2020.02.021","article-title":"The incidence of venous thromboembolism and impact on survival in hodgkin lymphoma","volume":"20","author":"Kirkizlar","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.thromres.2022.01.008_bb0120","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1160\/TH16-11-0895","article-title":"Khorana score and histotype predicts incidence of early venous thromboembolism in non-hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of fondazione italiana linfomi (FIL)","volume":"117","author":"Santi","year":"2017","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.01.008_bb0125","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12032-017-1065-4","article-title":"Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: validation of the khorana risk score","volume":"35","author":"Rupa-Matysek","year":"2017","journal-title":"Med. Oncol."},{"key":"10.1016\/j.thromres.2022.01.008_bb0130","doi-asserted-by":"crossref","first-page":"7585","DOI":"10.1002\/cam4.4280","article-title":"Incorporating genetic and clinical data into the prediction of thromboembolism risk in patients with lymphoma","volume":"21","author":"Bastos-Oreiro","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.thromres.2022.01.008_bb0135","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/ajh.25837","article-title":"Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma - specific venous thrombosis prediction models","volume":"95","author":"Dharmavaram","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.thromres.2022.01.008_bb0140","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/ajh.24466","article-title":"Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients","volume":"91","author":"Antic","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.thromres.2022.01.008_bb0145","doi-asserted-by":"crossref","DOI":"10.1177\/10760296211045908","article-title":"The application of the ThroLy risk assessment model to predict venous thromboembolism in patients with diffuse large B-cell lymphoma","volume":"27","author":"Abdel-Razeq","year":"2021","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2022.01.008_bb0150","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1002\/cam4.1540","article-title":"Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice","volume":"7","author":"Rupa-Matysek","year":"2018","journal-title":"Cancer Med."},{"key":"10.1016\/j.thromres.2022.01.008_bb0155","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1182\/asheducation-2010.1.437","article-title":"Thrombosis in multiple myeloma","volume":"2010","author":"Kristinsson","year":"2010","journal-title":"Hematology"},{"key":"10.1016\/j.thromres.2022.01.008_bb0160","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1182\/blood-2009-11-252072","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study","volume":"115","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2022.01.008_bb0165","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.thromres.2022.01.008_bb0170","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.thromres.2022.01.008_bb0175","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood.2020005125","article-title":"Thrombosis in patients with myeloma treated in the myeloma IX and myeloma XI phase 3 randomized controlled trials","volume":"136","author":"Bradbury","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2022.01.008_bb0180","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2141.2006.06208.x","article-title":"Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism","volume":"134","author":"Elice","year":"2006","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2022.01.008_bb0185","article-title":"Incidence and risk factors of thromboembolism with multiple myeloma in the presence of death as a competing risk: an empirical comparison of statistical methodologies","volume":"4","author":"Brown","year":"2016","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.thromres.2022.01.008_bb0190","doi-asserted-by":"crossref","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","article-title":"Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma","volume":"17","author":"Li","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.thromres.2022.01.008_bb0195","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1177\/1076029614521280","article-title":"Venous thromboembolism in patients with myeloma: incidence and risk factors in a \"real-world\" population","volume":"20","author":"Crowley","year":"2014","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2022.01.008_bb0200","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.thromres.2022.01.008_bb0205","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/cncr.20405","article-title":"Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease","volume":"101","author":"Srkalovic","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.thromres.2022.01.008_bb0210","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1538-7836.2011.04215.x","article-title":"Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis","volume":"9","author":"Carrier","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2022.01.008_bb0215","first-page":"414","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leuk. Off. J. Leuk. Soc. Am. Leuk. Res. Fund UK"},{"key":"10.1016\/j.thromres.2022.01.008_bb0220","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.thromres.2022.01.008_bb0225","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/bjh.17505","article-title":"Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study","volume":"193","author":"Covut","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2022.01.008_bb0230","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1002\/ajh.25658","article-title":"Predicting the risk of venous thromboembolism in newly diagnosed myeloma with immunomodulatory drugs: external validation of the IMPEDE VTE score","volume":"95","author":"Chalayer","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.thromres.2022.01.008_bb0235","series-title":"Multiple Myeloma, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","author":"Kumar","year":"2021"},{"issue":"1","key":"10.1016\/j.thromres.2022.01.008_bb8000","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12634","article-title":"Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma","volume":"6","author":"Sanfilippo","year":"2022","journal-title":"Res. Pract. Thromb. Haemost."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822000081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822000081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:47:42Z","timestamp":1758736062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384822000081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":48,"alternative-id":["S0049384822000081"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2022.01.008","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Venous thromboembolism and risk stratification in hematological malignancies","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2022.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}